Best of both worlds

The nondescript Cadila Healthcare is the third-largest player in domestic formulation and figures in the top 15 generic companies in the US. Its revenue grew by an average 21 per cent annually in the last ten years. Cadila was able to achieve this feat by taking an unusual route to ramping up its US revenues, the benefits of which it reaps to this day. Why Cadila can continue to be an Unusual Winner The unusual route to US growth: Cadila took the unusual route to growing its US revenues. Whereas other Indian pharma companies manufactured their own generic versions of the drugs going off-patent, Cadila tied up with patent holders to manufactu